GlassScriptPhysician profile
Paul A Simonoff
NPI 1811980055
$2,655.05
in general payments reported to CMS, 2019-2025
27 companies · $348 in 2025
The $348 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $866 · 2020: $99.36 · 2021: $283 · 2022: $175 · 2023: $425 · 2024: $459 · 2025: $348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,232.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $417.34 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $392.18 | 2019-2024 | |
| Boston Scientific Corporation | $309.14 | 2019-2023 | |
| W. L. Gore & Associates, INC. | $208.45 | 2019-2021 | |
| Pfizer INC. | $156.51 | 2021-2024 | |
| Inspire Medical Systems, INC. | $145.07 | 2024-2025 | Inspire |
| Abbott Laboratories | $114.82 | 2024-2025 | Xience Skypoint, Thoratec Heartmate 3 Lvas Implant Kit |
| Abiomed | $114.03 | 2021-2024 | Impella |
| Akcea Therapeutics, INC. | $109.61 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $105.75 | 2019-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $105.28 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $47.87 | 2019-2025 | Camzyos |
| Heartflow, INC. | $40.50 | 2023-2025 | Ffrct |
| Gilead Sciences, INC. | $39.87 | 2019 | |
| Janssen Pharmaceuticals, INC | $39.55 | 2019-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.00 | 2019-2021 | |
| Medtronic Vascular, INC. | $34.99 | 2019 | |
| Novo Nordisk INC | $32.51 | 2024 | Rybelsus, Ozempic |
| Ionis Pharmaceuticals, INC. | $26.77 | 2025 | Tryngolza |
| Kiniksa Pharmaceuticals International, Plc | $24.88 | 2024 | Arcalyst |
| Edwards Lifesciences Corporation | $24.78 | 2025 | Pascal |
| Inari Medical, INC. | $22.61 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Regeneron Healthcare Solutions, INC. | $21.91 | 2023 | Praluent, Evkeeza |
| Merck Sharp & Dohme LLC | $21.42 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $20.76 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $20.06 | 2024 | Opsumit |
| Sanofi-Aventis U.S. LLC | $19.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Simonoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.